Skip to main content
Caplight Logo









Eatmaple

Eatmaple

Private
SeoulHealthcare & Life Scienceshttps://microsalts.com

Last Round

Series A

Mar 20, 2015

Est. Valuation

$115M

Total Funding Raised

$26M

Company Overview

Eatmaple operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Series A round in March 2015.

Eatmaple is a South Korean food tech company that provides data-driven, personalized meal services for patients with specific health conditions.

Sector

Healthcare & Life Sciences

Verticals

D2C Brands, Subscription Commerce, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Eatmaple Comparables

Compare Eatmaple with similar companies based on industry and business-model similarity.

Eatmaple comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Medisola
85%
Hyundai Green Food Co., Ltd.
76%
Pulmuone Co., Ltd.
76%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Eatmaple Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 20, 2015
SeedNov 1, 2014
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Eatmaple Investors

Notable investors and investment history

Eatmaple investors
InvestorRounds
Greenoaks Capital PartnersSeries A
Thrive CapitalSeries A, Seed
AGO PartnersSeries A
Primary Venture PartnersSeries A
14WSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 1, 2014

    $4M round with participation from Thrive Capital.

Book a demo to see all signals

For institutional investors. Book with your work email.

Eatmaple Filings

Explore SEC and related filing metadata, where available.

Eatmaple filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Eatmaple's valuation, stock price, and market status.

Is Eatmaple a public or private company?

Eatmaple is a private company.

What is the current stock price of Eatmaple?

Eatmaple is a private company, so its shares have no public market price. Caplight tracks Eatmaple's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Eatmaple worth (valuation)?

Eatmaple's valuation is estimated at $115.0M based on funding round data.

Can I buy Eatmaple stock?

Eatmaple shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Eatmaple's last funding round?

Eatmaple's most recent funding round was Series A on March 20, 2015.

Who are the main investors in Eatmaple?

Key investors in Eatmaple include Greenoaks Capital Partners.

Will Eatmaple IPO soon?

No public IPO plans have been announced for Eatmaple.

How can I track Eatmaple secondary market activity?

Caplight tracks bids, offers, and trades in Eatmaple's shares on secondary markets.

Firmographic Details

HeadquartersSeoul
Year Founded2020
Last FundingMar 20, 2015

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?